In a nutshell This study examined a new treatment combination known as RCC followed by rituximab (Rituxan) maintenance therapy for chronic lymphocytic leukemia (CLL). These results support the safety and effectiveness of RCC followed by rituximab maintenance therapy. Risk factors of disease progression were identified. Some background The chemotherapy...
Read MoreRituximab, cladribine and cyclophosphamide: Early results of a new treatment combination with and without maintenance therapy
